Showing results (331-340 of 357) with videos related to

Sort By:
Pageof 36
Journal of Virology|December 26, 2024
The persistent pool of HIV-1-infected cells is formed episodically during untreated infectionOlivia D Council, Lynn Tyers, Matthew Moeser, et al.
The Journal of Infectious Diseases|March 13, 2014
HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostatNancy M Archin, Rosalie Bateson, Manoj K Tripathy, et al.
The Journal of Infectious Diseases|June 5, 2020
Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral TherapyShane D Falcinelli, Bonnie E Shook-Sa, Morgan G Dewey, et al.
Mbio|September 22, 2022
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) StudyLuther A Bartelt, Alena J Markmann, Bridget Nelson, et al.
Plos Pathogens|January 4, 2014
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsCelsa A Spina, Jenny Anderson, Nancie M Archin, et al.
The Journal of Infectious Diseases|February 13, 2024
The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral TherapyCynthia L Gay, Patrick J Hanley, Shane D Falcinelli, et al.
Msphere|August 25, 2021
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent IndividualsAlena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Medrxiv : the Preprint Server for Health Sciences|February 10, 2021
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individualsAlena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Plos One|December 8, 2022
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical centerHeather B Root, Matt Gilleskie, Chih-Huan Lu, et al.
Scientific Reports|March 22, 2020
Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 InfectionCynthia L Gay, Joann D Kuruc, Shane D Falcinelli, et al.
Pageof 36